Wisconsin Newborn Screening Study

Specimen Information

Status: Specimens are Available
Specimens were collected associated with clinical care over a longitudinal time period of at least 17 years. Left over specimen (plasma) was saved when available; thus the timeframe for specimen collection is variable. In the table below Visit 1 (baseline) represents the first sample taken and Visit 2 represents all other potential time points during this longitudinal study.

<table>
<thead>
<tr>
<th>Visit #</th>
<th>Time From Baseline</th>
<th>Specimens Collected</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>+0 Days</td>
<td>EDTA plasma</td>
</tr>
<tr>
<td>2</td>
<td>+17 Years</td>
<td>EDTA plasma</td>
</tr>
</tbody>
</table>

Study Design

Study Type? Interventional
Randomized Study? No
Placebo Controlled? No
Length of Participation
Number of Study Visits?

Additional Information

Phase? Not Applicable
Study Sponsor? Farrell, Philip
Study Drugs? N/A

Eligibility

Age 1 Years to 21 Years
Mutation(s) No Mutation Requirement
FEV1% Predicated No FEV1 Limit
PA Status Not Applicable
Other Other key inclusion criteria include: must have been born in the State of Wisconsin, must have been born between April 15, 1985 and June 30, 1994, must have had a valid newborn screening test for cystic fibrosis in the first 28 days of life and must have a sweat chloride test greater or equal to 60 mmol/Liter
Study Results

CITATION:
Pediatrics 2001, Jan(107(1)):1-13

For more information about the results of this study and where it was conducted, visit ClinicalTrials.gov.